Clinical trials
Metastatic clinical trials
Below are recruiting metastatic clinical trials, each written for real people, not researchers. We’re tracking 2,364 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07311577RecruitingPhase 2
Trial of a drug combo for HER2-positive ovarian cancer
This trial tests a combination of disitamab vedotin, platinum chemotherapy, and bevacizumab as first treatment for high-risk ovarian cancer that has a protein called HER2. The goal is to see if this therapy helps control the cancer and keeps it from growing.
Nanjing, JiangsuAges 18–75 - NCT06747845RecruitingPhase 2
Maintenance therapy for stable metastatic pancreatic cancer
This trial tests a combination of two drugs, niraparib and ipilimumab, as a maintenance treatment for people with metastatic pancreatic cancer that has not grown after initial chemotherapy. The goal is to see if this can help keep the cancer stable longer.
Boston, MassachusettsAges 18 years+ - NCT06016855RecruitingPhase 4
Surgery before radiation therapy for neuroendocrine tumors
This trial tests if removing as much tumor as possible through surgery before a targeted radiation therapy (PRRT) can help people with well-differentiated neuroendocrine tumors that have spread to the liver. The goal is to see if this approach works better than radiation therapy alone.
Nashville, TennesseeAges 18 years+ - NCT07481799RecruitingPhase 3
Targeted drug plus focused radiation for EGFR-positive cancer that has spread a little
This study tests a new targeted drug (MRG003) combined with precise radiation (SBRT) for people with EGFR-positive solid tumors that have spread to a few new spots. The goal is to see if this combination works better than standard treatments to control the cancer.
Zhuhai, GuangdongAges 18–75 - NCT07469774RecruitingPhase 1/Phase 2
BC3195 plus Keytruda for advanced solid tumors
This trial is testing a new drug called BC3195 combined with pembrolizumab (Keytruda) for people with advanced solid tumors that haven't responded to other treatments. It aims to see if the combination can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18 years+ - NCT07459751RecruitingPhase 2/Phase 3
A study of HLX43 alone or with HLX07 vs docetaxel for advanced squamous lung cancer
This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06367972RecruitingPhase 2/Phase 3
Extending systemic therapy with local treatment for limited cancer growth
This trial tests whether adding local treatments like radiation or surgery to standard therapy can help control cancer that has started to grow in just a few spots. It is for people with certain advanced cancers that have 1 to 5 growing lesions that can be treated locally.
Houston, TexasAges 18 years+ - NCT06724016RecruitingPhase 1
Study of HM16390 alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug, HM16390, either by itself or combined with pembrolizumab, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if it can shrink tumors.
Boston, MassachusettsAges 18 years+ - NCT06670911RecruitingPhase 2
Lower dose pembrolizumab with chemo for advanced cervical cancer
This trial tests a lower dose of pembrolizumab combined with standard chemotherapy as a first treatment for cervical cancer that has spread, come back, or cannot be removed by surgery. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.
Rio de Janeiro, Rio de JaneiroAges 18 years+ - NCT06735391RecruitingPhase 3
JMT101 plus osimertinib vs osimertinib for EGFR-mutant lung cancer
This trial tests a new combination of two targeted drugs (JMT101 and osimertinib) against osimertinib alone for people with advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better as a first treatment.
GuangzhouAges 18 years+ - NCT06934538RecruitingPhase 1/Phase 2
Immunotherapy trial for advanced colorectal cancer
This trial tests a new immunotherapy drug (STC-1010) for people with colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the drug can shrink tumors or slow the disease.
Baltimore, MarylandAges 18–75 - NCT06974812RecruitingPhase 1/Phase 2
Study of IBI3014 for advanced solid tumors
This trial tests a new drug called IBI3014 for people with advanced solid tumors that cannot be removed by surgery. It aims to see if the drug is safe and effective.
Fuzhou, FujianAges 18 years+ - NCT06613113Recruiting
Fruquintinib, adebrelimab, and radiation for advanced colorectal cancer
This trial tests a combination of two drugs (fruquintinib and adebrelimab) plus low or high dose radiation for people with advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow the disease.
Ningbo, ZhejiangAges 18 years+ - NCT06258304RecruitingPhase 1
Testing a new immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug, GIGA-564, for people with advanced solid tumors that have not responded to or have returned after standard treatments. The goal is to see if the drug is safe and effective, and to find the best dose.
Bethesda, MarylandAges 18 years+ - NCT04704505RecruitingPhase 2
Testosterone-like treatment plus radium for bone-spread prostate cancer
This trial studies whether adding a testosterone-related therapy (BAT) to radium-223 can better control prostate cancer that has spread mainly to the bones. It may help shrink tumors in the bone and slow PSA rises, which are a common marker of prostate cancer activity.
Baltimore, MarylandAges 18 years+ - NCT06978296Recruiting
HIMARS: Stereotactic radiation for prostate cancer spread
This trial tests adding targeted radiation (SRT) to bone or lymph node metastases in men with prostate cancer that has continued to grow despite hormone therapy, chemo, or other treatments. The goal is to see if radiation can help control the disease and improve outcomes.
Saint-HerblainAges 18 years+ - NCT06248411RecruitingPhase 1
Study of KK2260 for advanced solid tumors
This study tests a new experimental drug, KK2260, for people with advanced or advanced solid tumors, especially esophageal cancer and certain head and neck cancers. The goal is to see if the drug is safe and helps shrink or control the cancer.
Nagoya, Aichi-kenAges 18 years+ - NCT06661122Recruiting
Darolutamide with ADT and docetaxel for low-volume metastatic prostate cancer
This study looks at how safe and effective the combination of darolutamide (a tablet), hormone therapy (ADT), and chemotherapy (docetaxel) is for Japanese men with prostate cancer that has spread in a limited way (low volume). It observes people in regular medical care, not in a research setting.
Multiple LocationsAges 18 years+ - NCT07043400RecruitingPhase 3
Study comparing two ways to give tislelizumab plus chemo for stomach cancer
This trial compares a shot under the skin versus an IV infusion of tislelizumab, given along with chemotherapy, for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the shot works as well as the IV and may be more convenient.
Chandler, ArizonaAges 18 years+ - NCT07137871RecruitingPhase 1
Avasopasem for advanced HR+ breast cancer after CDK 4/6 inhibitor
This trial tests a drug called avasopasem for people with hormone receptor-positive, HER2-negative breast cancer that has spread and gotten worse despite treatment with a CDK 4/6 inhibitor (ribociclib or abemaciclib) and hormonal therapy. It aims to see if adding avasopasem can help control the cancer.
San Antonio, TexasAges 18 years+ - NCT04428554RecruitingPhase 2
Radiation to control bladder cancer spread after no growth
This trial tests whether giving focused radiation (SBRT) to a few remaining metastatic spots can stop bladder cancer from progressing after initial chemotherapy or immunotherapy has worked. It may help patients who still have up to three remaining distant lesions but are not getting worse.
AlbiAges 18 years+ - NCT05785754RecruitingPhase 1
Early drug study for advanced solid tumors
This Phase 1 study tests DCSZ11 in people with advanced or metastatic solid tumors (cancers that can’t be removed or have spread) given alone or with other treatments. It’s designed to find a safe dose and to see whether the treatment shows signs of shrinking cancer.
Birmingham, AlabamaAges 18 years+ - NCT06640725RecruitingPhase 2
TPEx chemo with maintenance immunotherapy for advanced head and neck cancer
This trial tests a combination of chemotherapy drugs (TPEx) followed by two immunotherapy drugs (avelumab and cetuximab) as a first treatment for head and neck cancer that has spread or come back. It is for people whose tumors show a protein called PD-L1 and who have not had chemotherapy for advanced disease before.
Vandœuvre-lès-NancyAges 18–74 - NCT06586593Recruiting
Immunotherapy before surgery for advanced melanoma
This study looks at how well immunotherapy works before surgery for melanoma that has spread. If you have stage III or IV melanoma that can be removed, you may be able to join this trial.
AngersAges 18 years+
Hear when a new Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic?
- Yes. Clin2 currently lists 2,364 recruiting metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.